Background and Objectives-Extended-release (XR) injection naltrexone has proved promising in the treatment of opioid dependence. Induction onto naltrexone is often accomplished with a procedure known as rapid naltrexone induction. The purpose of this study was to evaluate pre-treatment patient characteristics as predictors of successful completion of a rapid naltrexone induction procedure prior to XR naltrexone treatment.
INTRODUCTION
Opioid dependence is a serious and major global public health concern. 1 The mainstays of treatment for opioid dependence in the United States and Canada have been detoxification followed by psychosocial treatment, or agonist (methadone or buprenorphine) maintenance therapy. 2 Detoxification followed by psychosocial treatment carries the appeal of getting patients "drug-free" and, while a successful approach for some individuals, is associated with a high relapse rate. 3, 4, 5 Opioid agonist treatment with buprenorphine or methadone is often effective for treatment seeking patients. However, some patients have difficulty accessing opioid maintenance treatment centers or providers. Many patients fail to achieve abstinence with these treatments and some who are maintained on opioid agonist treatment eventually no longer want to remain physically dependent on buprenorphine or methadone. 6, 7 In such cases, detoxification with an opioid antagonist provides a suitable alternative treatment. In the past, antagonist maintenance therapy with naltrexone was thought to be primarily successful for subsets of patients with high motivation (eg, professionals whose employment might prohibit abuse). However, recent developments, including the combination of naltrexone with behavioral incentives, 8, 9, 10, 11, 12 and the advent of long-acting injectable naltrexone, 13 have improved long-term adherence levels close to what can be expected for agonist treatment. 14 Thus, naltrexone holds broader promise as an alternative maintenance therapy for opioid dependence.
A critical challenge with the antagonist treatment approach, however, is that a patient needs detoxification from opioids prior to induction onto naltrexone, in order to avoid precipitated withdrawal. It is recommended that 7-10 days of abstinence from opioids are needed to ensure a safe and comfortable induction. 15 However, detoxification followed by such a long delay carries a high risk of relapse if patients are discharged to outpatient care. The cost of longer inpatient stays are often not supported by third-party payors. A rapid detoxification and naltrexone induction procedure was thus developed to minimize the length and discomfort of opioid detoxification, 16 and has been refined over the years. 17, 18 Nonetheless, this procedure remains associated with high rates of dropout 19, 20, 21 and we do not have a good understanding of factors that may contribute to premature treatment termination.
It is important for addiction specialists to understand the complex psychological, behavioral and social factors that contribute to attrition in any treatment program. It is especially important in the context of strengthening a promising but underutilized approach such as opioid antagonist treatment. If there are characteristics of patients that predict which patients are more versus less likely to successfully initiate naltrexone treatment using rapid induction method, this could prove important to efforts to improve naltrexone induction procedures and reduce dropout. Such characteristics could be valuable in tailoring treatment to the patient, for instance by delaying naltrexone induction for patients who likely need a slower detoxification. Patient characteristics associated with dropout may also offer clinicians insight into the mechanisms underlying difficulties with naltrexone induction. We therefore examined demographic and clinical characteristics of opioid dependent patients at baseline as predictors of successful and unsuccessful induction onto naltrexone in a series of patients entering clinical trials of naltrexone maintenance.
METHODS

Participant Selection and Study Procedures
A retrospective clinical chart review of 150 opioid-dependent patients seeking detoxification and treatment within the context of three clinical trials (Trial Identification Numbers: NCT00476242, NCT00332228, NCT00577408) at the Substance Treatment and Research Services (STARS) clinic, housed at the New York State Psychiatric Institute (NYSPI), was conducted. This sample was selected from consecutive research study admissions of treatment-seeking opioid-dependent adults (aged 18-60) between January 2007 and December 2009. Patients were recruited through word of mouth and advertisements in local media, and if deemed eligible, gave written informed consent to one of three opioiddependence treatment studies, each offering injection naltrexone after a successful detoxification and oral naltrexone induction. The trials each shared identical screening processes, and nearly identical inpatient and outpatient procedures. The most salient points of difference were as follows. The longest-running study of 24 weeks ("Trial A") had a fourcell treatment design with arms involving random assignment to either oral or injection naltrexone (Depotrex™), and arms also involving random assignment to either the treatment-as-usual of Compliance Enhancement therapy (CE) versus a newer, more comprehensive behavioral therapy, Behavioral Naltrexone Therapy (BNT). Trials B and C were simpler standard two-cell protocols. Trial B was a 24-week trial and was designed as a follow-up to Trial A, using the more comprehensive BNT instead of CE and including random assignment to either oral or injection naltrexone (now the more well-known formulation of Vivitrol™ instead of Depotrex™). Trial B involved no other medications under research, and like Trial A provided for a standardized schedule for ancillary meds. 22 In Trial C was a 12-week study in which all patients received extended-release naltrexone; the main study drug was the NMDA glutamate receptor antagonist memantine which was started on day 5 of study participation. 21 This third study also allowed participants more flexibility in receiving ancillary pharmaceutical treatment than the former two trials did. Research inclusion and exclusion criteria for these studies were similar, as each of the trials sought treatment-seeking opioid-dependent individuals. Participants presenting with unstable medical or psychiatric conditions that might have interfered with naltrexone induction and treatment were excluded from all studies. Those prospective patients on methadone or buprenorphine maintenance were excluded, as were those taking more than 30 mg per day of illicit methadone, as methadone usage was previously associated with poor success rate on naltrexone 23 , presumably due to its long half-life and increased likelihood of precipitated withdrawal during a rapid naltrexone induction. Those with a history of opioid overdose were also excluded as a riskminimizing measure for post study participation. These studies were approved by the New York State Psychiatric Institute IRB.
Screening Procedures
At the baseline screening assessment, each prospective participant met with a masters level therapist for a comprehensive diagnostic interview (SCID). At this time, demographic information and data on opioid dependence was collected (eg, longest period of abstinence, duration and route of drug use, quantity of current drug use-translated into equivalent number of heroin bags). Since some of the participants were oral (PO) users (opioid analgesics, as opposed to heroin), the opioid of choice (i.e. hydrocodone, oxycodone, etc.) as reported by the participant was converted to oral morphine equivalents. We estimated that 20 mg of oral morphine was equivalent to one bag of heroin. For oral preparations 30 mg of morphine was equivalent to 40 mg of hydrocodone or 20 mg of oxycodone. Cross-tolerance was not accounted for in the conversion of prescription narcotics to bags of heroin. Information regarding concurrent and past drug use, past attempts at detoxification and rehabilitation, family drug use, presence of legal troubles, and Hamilton Depression Scale was also collected. Additionally, a full medical and psychiatric evaluation was conducted by a physician.
Rapid Naltrexone Induction Procedure
Eligible participants gave informed consent and were admitted to an inpatient research unit for an approximately 7-day duration of the detoxification and naltrexone induction procedure. The Rapid Induction Protocol 18 followed the guideline outlined in Table 1 . Thus, on the day of admission (day 1), non-opioid medications (clonidine, clonazepam, ranitidine, ibuprofen, and zolpidem and trazodone) were started and continued throughout the inpatient period. On day 2, 16-24 h after the patient ceased opioid use, and as withdrawal signs and symptoms escalate, low-dose buprenorphine was administered (4 mg in the morning and 4 mg in the evening). After a one day of wash-out (Day 3) oral naltrexone was initiated slowly with 3 mg on day 4, and incrementally increased to 6 mg on day 5 and 25 mg on day 6. Naltrexone precipitated withdrawal symptoms were managed with additional doses of nonopioid medications (mostly clonidine and clonazepam). Patients who completed this Rapid Naltrexone Induction protocol successfully were then randomly inducted onto either oral or injectable naltrexone. On day 7, patients received either two consecutive 50 mg doses of maintenance oral naltrexone (N = 47) or a single dose of the extended-release naltrexone intramuscular (IM) injection (Depotrex™ or Vivitrol™) (N = 37), and subsequently discharged for outpatient treatment (Table 1) . Patients who completed the inpatient naltrexone induction procedure, received the target dose of naltrexone and were discharged to outpatient treatment and were considered to have completed the detoxification-induction procedure; all others were considered non-completers.
Data Analysis
The primary outcome measure for this analysis was binary categorical completion status during the inpatient detoxification phase (ie, completers vs. non-completers). To test for simple associations between completion status and the panel of baseline demographic and clinical predictor variables, we used independent t-tests for continuous variables and Chi square tests for categorical variables (or Fisher's exact test for categories with n < 5). All tests were two-tailed and set at α = 0.05 for this exploratory analysis. We then performed a logistic regression (SAS ® PROC LOGISTIC) with completion status as the outcome, building a preliminary main-effects model by including all predictor variables significant at p <.25, and conducting a backward elimination procedure to arrive at a final model including only those predictor variables significant at p-values <.05. The purpose of this step-wise procedure was to determine which predictors were most important, remaining significant after control for other predictors.
RESULTS
Of the 150 opioid-dependent patients included in the analysis, 84 (56%) completed the inpatient Rapid Naltrexone Induction procedure, and 66 were identified as non-completers. Table 2 summarizes the comparisons of demographic and clinical characteristics between the completers and noncompleters. Completers were significantly older, used less opioid at baseline, were more likely using exclusively opioids versus those who also used other substances, and were less likely to be using cannabis. Completers had a later age-at-onset of opioid dependence (but more years of regular opioid use, quantified as the difference between age at first use and current age), more educational attainment, less history of legal problems, less current nicotine use, and less history of prior inpatient rehabilitation program participation. Notably, there were no apparent differences between completers and noncompleters in the prevalence of current mood or anxiety disorders, nor mood symptoms as measured by the Hamilton Depression Scale. There was also no evidence of association between completers and non-completers in the type of opioid used (heroin compared to prescription opioid users). A multivariate regression analysis was conducted to determine an interaction between number of bags and type of opioid use, eg. to see whether the effect of number of bags changes depending on opioid type. The interaction terms was not significant (p = 0.356). Failure to complete appeared slightly more likely among intravenous users, but this did not approach significance.
The final logistic regression analysis (Table 3) yielded two statistically significant baseline characteristics that were associated with completion of the Rapid Naltrexone Induction protocol: the pre-admission level of opioid use and age. Older patients, and those using less opioid at baseline, were found to be more likely to complete the naltrexone induction. Figure  1 shows box-plots of the distribution of these two variables comparing completers vs noncompleters. The distribution for baseline daily opioid use is particularly interesting, showing that about 75% of completers were using less than 10 bags per day at baseline, while around 50% of non-completers were using more than 10 bags per day, and the distribution for the non-completers had a longer upper tail-ie, patients with the highest level of daily opioid were in the early-dropout category.
DISCUSSION
The results indicate that older patients and those with lower daily opioid use are more likely to complete an inpatient rapid naltrexone induction procedure, while those older with greater levels of baseline opioid use were less likely to successfully induct onto naltrexone. The finding on baseline level of opioid use is consistent with studies from previous cohorts of patients at our clinic that examined predictors of retention in naltrexone-based treatment. 11, 14, 23, 24 To our knowledge our group has been the first to examine the predictive factors of successful naltrexone induction. There have been some studies from other groups that support our findings of less opioid use and older age as predictors for positive outcomes in short term buprenorphine detoxification. 25, 26 Similar studies evaluating treatment outcome in flexible dose-duration methadone detoxification programs have found higher baseline levels of methadone use (measured as average amount used per day), younger age, and longer duration of opioid use as predictors of poor treatment retention. 27 It is important to note that although Trial C studied the use of memantine, there was no effect observed in the completion status of the rapid naltrexone induction procedures of memantine compared to placebo conditions. 21 The previous clinical trials examined retention which varied between 44 and 70% for all three studies with 3-month naltrexone maintenance and varied between 17 and 46% in the two studies with 6-month naltrexone maintenance. 21, 22 Retention was measured across the entire treatment episode which included both inpatient naltrexone induction and outpatient naltrexone maintenance. These findings corroborate previous literature which suggests that a substantial number of patients treated with naltrexone are able to remain in treatment and in abstinence. 28, 29 These rates are comparable to retention rates for patients treated with buprenorphine. 30, 31, 32 The present study, however, focuses specifically on completion of the initial inpatient detoxification.
The goal of the rapid naltrexone induction procedure is to provide a rapid but tolerable transition onto the platform of naltrexone. 18, 16 It uses non-opioid medications, clonidine and clonazepam, and others, from the outset to attenuate both spontaneous and any precipitated withdrawal that occurs as naltrexone is introduced. A modest dose of buprenorphine is given only for one day (generally late in Day 1, or Day 2) to treat the worst of the withdrawal. Since the severity of withdrawal is related to the level of physiological dependence, it makes physiological sense that patients with higher baseline levels of opioid use are likely to experience greater withdrawal discomfort during this rapid detoxification-naltrexone induction procedure. Individuals who use higher amount of opioids at baseline might also be less able to tolerate withdrawal symptoms (lower distress tolerance).
The clinical implication would be that for patients with higher levels of opioid use at baseline, a slower induction procedure, allowing for further time before initiating naltrexone, and higher doses of adjunctive medications, including higher dose and/or longer duration of buprenorphine administration, should be considered. For example, instead of beginning naltrexone on the 4th day of admission, as was the target for patients in the present study, naltrexone could be started on the 6th or 7th day, or later, or the starting naltrexone dose could be lower than 3 mg. Buprenorphine might be given for 2 or 3 days, if needed, rather than just one. Guidelines to this effect have recently been published. 18 An alternative procedure, such as an extended cross-taper from buprenorphine to naltrexone could also be utilized to minimize the severity of discomfort emerging during the induction onto naltrexone. 33, 34 It is also important to note that ultra-rapid naltrexone induction under general anesthesia has been attempted and proposed for individuals who are unable to tolerate standard detoxification procedures. However, evidence suggests that anesthesiabased detoxification is no more effective at reducing withdrawal symptoms than more gradual detoxification-naltrexone induction methods, and is potentially dangerous in that serious medical complications have been observed. 18, 19 Older age has been associated with better retention in treatment for other substance problems and treatment settings. 35, 36 This might reflect the "aging out" phenomenon, or greater maturity or motivation for treatment. Clinically, a recommendation might be to consider a more gradual detoxification-induction for younger patients.
It is also important to note that baseline opioid use and age only explain a fraction of the variance in naltrexone induction completion. Inspection of the relevant box plots (Fig. 1) suggests that while patients with more than 15 bags per day of heroin use at baseline almost invariably failed to complete, a number of patients in the heavy-use range of 7 to 15 bags per day did succeed. Conversely, a number of patients taking less than 7 bags per day at baseline failed to complete. For the "age" variable, the distributions for completers and noncompleters substantially overlap. Thus, there are likely unmeasured individual factors contributing to completion status, such as impulsivity, distress tolerance or susceptibility to withdrawal symptoms. During inpatient detoxification all participants received standing and as needed doses of ancillary medications. The use of these medications was only restricted due to safety concerns (eg, standing doses of clonidine were held if blood pressure was below cut-off). The majority of patients took all doses of available adjunctive medications and even with that there remains a significant level of withdrawal. It is possible that more severe withdrawal results in treatment drop-out but we do not have readily available data to assess that in the present manuscript. One recommendation based on this analysis would be to closely monitor withdrawal discomfort during the first 24 h of the rapid induction procedure. Patients with continued high levels of discomfort should be considered for more aggressive withdrawal treatment with more buprenorphine, or even methadone, and a longer, more gradual detoxification with greater delay to naltrexone induction.
Younger age at first opioid use, years of continuous opioid use, history of legal problems, and non-opioid drug abuse, showed non-significant associations with failure to complete naltrexone induction. While no firm conclusions can be drawn given the sample size used, it is noteworthy that these findings are suggestive of greater overall severity, and bear further investigation.
Depression was predictive of worse retention in treatment in an earlier study, 23 however, depression diagnosis, depression severity, and anxiety disorder diagnosis was not predictive of naltrexone induction completion status in the present study. Patients with depression were eligible for the studies that made up the present cohort, as long as they were not acutely suicidal or otherwise in need of emergent treatment. There has been a concern that naltrexone may worsen depression, although we have found that depressive symptoms generally improve gradually in the weeks after induction onto naltrexone 37 , and that persistent depression can be treated with routine antidepressants.
Limitations of the present study include the lack of measurement of potentially relevant factors, as noted above eg. distress tolerance, impulsivity, chronic pain, and environmental factors (ie, milieu environment). We also do not have a systematic record of patients' stated reasons for premature termination from detoxification, thus missing an important subjective component from our analysis. The generalizability of our results is limited by the nature of our sample which was recruited and treated within a research service in federally-supported clinical trials, rather than community-based treatment programs. More studies are required on this topic to further support the findings from this secondary analysis and to determine whether the results from our use of statistical algorithms are consistent beyond just our specific sample. And several segments of the general opioid-misusing population, eg. patients with severe medical or psychiatric disorders, pain requiring opioid management, and past history of overdoses, were excluded.
In summary, lower level of opioid use and older age were associated with greater likelihood of completing a rapid naltrexone induction procedure that uses buprenorphine, clonidine and other non-opioid medications to manage withdrawal symptoms. The findings focus on the importance of evaluating severity of opioid dependence when planning to induce an actively using opioid-dependent patient onto naltrexone. Patients with higher levels of opioid use may require more aggressive treatment of withdrawal and a longer delay before initiating naltrexone. The rapid naltrexone induction procedure studied here was implemented in an effort to make naltrexone induction fit within the confines of brief hospitalizations for detoxification typically covered by third party payors, which are attempting to contain costs. With the advent of the long-acting injectable formulation, naltrexone has become an increasingly viable alternative for the longterm management of opioid dependence. However, its successful implementation will require more attention to optimizing procedures for initiating naltrexone among actively using opioid-dependent patients. A comparison of the distribution of bags/bag-equivalents of heroin used per day and age (years) between opioid-dependent patients who completed (N = 84), and those who failed to complete (N = 66), an inpatient rapid naltexone induction procedure. Mogali 
TABLE 1
Protocol guideline for rapid naltrexone induction used in a clinical research unit at the New York State Psychiatric Institute (New York City) for antagonist treatment of opioid-dependence following controlled detoxification 
